Test Price
5,000 AED✅ Home Collection Available
Preimplantation Genetic Diagnosis (PGD) for Single-Gene Disorders in Dubai | 5000 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Clinical Certainty – 99.9% Diagnostic Sensitivity
ISO 9001:2015 accredited processing with Sanger Sequencing guarantees pure embryonic DNA analysis. Maternal contamination check eliminates false positives.
Hospital Extraction Only – Strict IVF Facility
Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Trophectoderm biopsy performed by skilled embryologists under sterile conditions.
Post-Test Clinical Guidance
Telephonic result interpretation by a DHA-licensed genetics specialist. Direct insurance billing verification via WhatsApp.
Test Overview & Methodology
Preimplantation Genetic Diagnosis (PGD) with maternal contamination check is a definitive molecular test that screens embryos for single-gene defects prior to uterine transfer during an IVF cycle. This assay uses Sanger sequencing of trophectoderm cells to detect pathogenic variants while an integrated maternal DNA control guarantees that only embryonic DNA is amplified, yielding unmatched diagnostic purity.
| Feature | Our PGD + Maternal Check | Standard PGD (No Contamination Control) |
|---|---|---|
| Molecular Method | Sanger Sequencing (gold standard for single-gene variants) | Often NGS-only array or incomplete maternal exclusion |
| Maternal DNA Interference | Systematically eliminated via dedicated contamination check | Potential for false-positive calls from cumulus/maternal cells |
| Turnaround Time | 15-20 days from biopsy receipt | 12-15 days (without purity step) |
| Diagnostic Confidence | >99.9% specificity for the tested mutation | ~97-98% due to residual maternal admixture |
| ISO Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable |
Physician Insight & Safety Protocols
A Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403)
“PGD offers families carrying known genetic conditions a powerful reproductive option, but it must always be paired with comprehensive genetic counseling and expert IVF care. A negative result substantially lowers the risk of an affected pregnancy, yet no test provides absolute certainty. Please continue any prescribed medications and share this report with your fertility specialist for a fully integrated care plan.”
Important Advisory
Do not discontinue prescribed medication or alter your treatment regimen without consulting your physician. All clinical decisions should be made jointly with your healthcare provider based on the full context of your medical history.
Safety & Exclusion Criteria
- Inability to obtain an adequate trophectoderm biopsy sample (embryo quality < Grade B).
- Active intrauterine infection or ongoing maternal inflammatory condition that contraindicates biopsy.
- Lack of informed consent or incomplete genetic pedigree information.
- Maternal use of anticoagulants that cannot be temporarily held per IVF protocol.
ER Red Flags (Post-Biopsy):
- Severe pelvic pain or heavy vaginal bleeding.
- Fever, chills, or signs of pelvic infection.
- Sudden shortness of breath or chest pain.
If any of these occur, seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What is PGD with maternal contamination check and why is it important?
PGD with maternal contamination check detects embryo single-gene disorders while eliminating false positives from maternal DNA. This is performed on a few cells biopsied from a day-5 blastocyst during IVF. The contamination check cross-references maternal genetic markers, confirming that only embryonic DNA is sequenced – crucial for conditions like cystic fibrosis, thalassemia, or BRCA mutations. Results guide which embryo is selected for transfer, maximizing the chance of a healthy pregnancy.
2. How is the trophectoderm biopsy performed and is it safe for the embryo?
Trophectoderm biopsy is a minimally invasive procedure on day-5 blastocysts that does not harm embryo development. A highly skilled embryologist uses a laser-assisted micromanipulation system to remove 3-8 cells from the outer layer, which will later form the placenta. The embryo remains intact and continues to the inner cell mass. Multiple studies confirm that experienced hands achieve < 1% implantation rate reduction. It is performed under sterile IVF lab conditions with no extra discomfort to the patient.
3. How does the maternal contamination check improve PGD accuracy?
The contamination check eliminates maternal cell DNA from the sample, preventing false-positive results and ensuring diagnostic precision. Maternal follicular or cumulus cells can accidentally mix with the trophectoderm biopsy, leading to a result that reflects the mother's genetics instead of the embryo's. Our laboratory performs a parallel analysis of maternal DNA and compares short tandem repeat markers; if maternal DNA exceeds the exclusion threshold, the result is invalidated and re-analysis is advised. This step lifts confidence from ~97% to >99.9%.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
All genetic testing at DNA Labs UAE is performed under strict adherence to UAE federal data protection and health information governance standards. Patient data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility (License No. 1143) ensures that every stage of the testing workflow meets the highest regulatory benchmarks for privacy, accuracy, and ethical practice.
Results are communicated only to the ordering physician or the patient through verified channels, and no genetic information is shared with third parties without explicit written consent.
Clinical & Logistical Metadata
| Test Name | Preimplantation Genetic Diagnosis (PGD) for Single-Gene Disorders with Maternal Contamination Check |
| Price (AED) | 5,000 |
| Turnaround Time | 15-20 days from biopsy receipt |
| Sample Type / Matrix | Trophectoderm Biopsy (Embryo Cells) |
| Methodology Used | Sanger Sequencing with Maternal Contamination Control via Short Tandem Repeat (STR) Analysis |
| ICD-10-CM Code | Z31.49 |
| LOINC Code | 90577-7 |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians